← Patent-cliff monitor Loss of exclusivity June 2040 latest FDA-listed patent expiry
Drug detail Brand name NEXLIZET Active ingredient BEMPEDOIC ACID; EZETIMIBE Strength 180MG;10MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval February 2020 Marketing status RX
Listed patents Patent Expires Type 12398087 June 2040 substance, product 12404227 June 2040 substance 11613511 June 2040 substance 11760714 June 2040 product 11926584 June 2040 use U-3873 10912751 March 2036 use U-3224 11744816 March 2036 use U-3692 7335799 December 2030 substance
Regulatory exclusivity Code Expires I-943 March 2027 I-945 March 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.